Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. / Talwelkar, Sarang S.; Mäyränpää, Mikko I.; Søraas, Lars; Potdar, Swapnil; Bao, Jie; Hemmes, Annabrita; Linnavirta, Nora; Lømo, Jon; Räsänen, Jari; Knuuttila, Aija; Wennerberg, Krister; Verschuren, Emmy W.

In: Cell Reports Medicine, Vol. 2, No. 8, 100373, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Talwelkar, SS, Mäyränpää, MI, Søraas, L, Potdar, S, Bao, J, Hemmes, A, Linnavirta, N, Lømo, J, Räsänen, J, Knuuttila, A, Wennerberg, K & Verschuren, EW 2021, 'Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments', Cell Reports Medicine, vol. 2, no. 8, 100373. https://doi.org/10.1016/j.xcrm.2021.100373

APA

Talwelkar, S. S., Mäyränpää, M. I., Søraas, L., Potdar, S., Bao, J., Hemmes, A., Linnavirta, N., Lømo, J., Räsänen, J., Knuuttila, A., Wennerberg, K., & Verschuren, E. W. (2021). Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. Cell Reports Medicine, 2(8), [100373]. https://doi.org/10.1016/j.xcrm.2021.100373

Vancouver

Talwelkar SS, Mäyränpää MI, Søraas L, Potdar S, Bao J, Hemmes A et al. Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. Cell Reports Medicine. 2021;2(8). 100373. https://doi.org/10.1016/j.xcrm.2021.100373

Author

Talwelkar, Sarang S. ; Mäyränpää, Mikko I. ; Søraas, Lars ; Potdar, Swapnil ; Bao, Jie ; Hemmes, Annabrita ; Linnavirta, Nora ; Lømo, Jon ; Räsänen, Jari ; Knuuttila, Aija ; Wennerberg, Krister ; Verschuren, Emmy W. / Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. In: Cell Reports Medicine. 2021 ; Vol. 2, No. 8.

Bibtex

@article{462cec753468482aa2a02005fa246e13,
title = "Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments",
abstract = "Functional profiling of a cancer patient's tumor cells holds potential to tailor personalized cancer treatment. Here, we report the utility of fresh uncultured tumor-derived EpCAM+ epithelial cells (FUTCs) for ex vivo drug-response interrogation. Analysis of murine Kras mutant FUTCs demonstrates pharmacological and adaptive signaling profiles comparable to subtype-matched cultured cells. By applying FUTC profiling on non-small-cell lung cancer patient samples, we report robust drug-response data in 19 of 20 cases, with cells exhibiting targeted drug sensitivities corresponding to their oncogenic drivers. In one of these cases, an EGFR mutant lung adenocarcinoma patient refractory to osimertinib, FUTC profiling is used to guide compassionate treatment. FUTC profiling identifies selective sensitivity to disulfiram and the combination of carboplatin plus etoposide, and the patient receives substantial clinical benefit from treatment with these agents. We conclude that FUTC profiling provides a robust, rapid, and actionable assessment of personalized cancer treatment options.",
keywords = "ALK, drug sensitivity and resistance testing, EGFR, ex vivo drug screening, functional diagnostics, KRAS, lung cancer, personalized medicine, pharmacogenomics, targeted therapy",
author = "Talwelkar, {Sarang S.} and M{\"a}yr{\"a}np{\"a}{\"a}, {Mikko I.} and Lars S{\o}raas and Swapnil Potdar and Jie Bao and Annabrita Hemmes and Nora Linnavirta and Jon L{\o}mo and Jari R{\"a}s{\"a}nen and Aija Knuuttila and Krister Wennerberg and Verschuren, {Emmy W.}",
note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",
year = "2021",
doi = "10.1016/j.xcrm.2021.100373",
language = "English",
volume = "2",
journal = "Cell Reports Medicine",
issn = "2666-3791",
publisher = "Cell Press",
number = "8",

}

RIS

TY - JOUR

T1 - Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments

AU - Talwelkar, Sarang S.

AU - Mäyränpää, Mikko I.

AU - Søraas, Lars

AU - Potdar, Swapnil

AU - Bao, Jie

AU - Hemmes, Annabrita

AU - Linnavirta, Nora

AU - Lømo, Jon

AU - Räsänen, Jari

AU - Knuuttila, Aija

AU - Wennerberg, Krister

AU - Verschuren, Emmy W.

N1 - Publisher Copyright: © 2021 The Author(s)

PY - 2021

Y1 - 2021

N2 - Functional profiling of a cancer patient's tumor cells holds potential to tailor personalized cancer treatment. Here, we report the utility of fresh uncultured tumor-derived EpCAM+ epithelial cells (FUTCs) for ex vivo drug-response interrogation. Analysis of murine Kras mutant FUTCs demonstrates pharmacological and adaptive signaling profiles comparable to subtype-matched cultured cells. By applying FUTC profiling on non-small-cell lung cancer patient samples, we report robust drug-response data in 19 of 20 cases, with cells exhibiting targeted drug sensitivities corresponding to their oncogenic drivers. In one of these cases, an EGFR mutant lung adenocarcinoma patient refractory to osimertinib, FUTC profiling is used to guide compassionate treatment. FUTC profiling identifies selective sensitivity to disulfiram and the combination of carboplatin plus etoposide, and the patient receives substantial clinical benefit from treatment with these agents. We conclude that FUTC profiling provides a robust, rapid, and actionable assessment of personalized cancer treatment options.

AB - Functional profiling of a cancer patient's tumor cells holds potential to tailor personalized cancer treatment. Here, we report the utility of fresh uncultured tumor-derived EpCAM+ epithelial cells (FUTCs) for ex vivo drug-response interrogation. Analysis of murine Kras mutant FUTCs demonstrates pharmacological and adaptive signaling profiles comparable to subtype-matched cultured cells. By applying FUTC profiling on non-small-cell lung cancer patient samples, we report robust drug-response data in 19 of 20 cases, with cells exhibiting targeted drug sensitivities corresponding to their oncogenic drivers. In one of these cases, an EGFR mutant lung adenocarcinoma patient refractory to osimertinib, FUTC profiling is used to guide compassionate treatment. FUTC profiling identifies selective sensitivity to disulfiram and the combination of carboplatin plus etoposide, and the patient receives substantial clinical benefit from treatment with these agents. We conclude that FUTC profiling provides a robust, rapid, and actionable assessment of personalized cancer treatment options.

KW - ALK

KW - drug sensitivity and resistance testing

KW - EGFR

KW - ex vivo drug screening

KW - functional diagnostics

KW - KRAS

KW - lung cancer

KW - personalized medicine

KW - pharmacogenomics

KW - targeted therapy

U2 - 10.1016/j.xcrm.2021.100373

DO - 10.1016/j.xcrm.2021.100373

M3 - Journal article

C2 - 34467250

AN - SCOPUS:85112829958

VL - 2

JO - Cell Reports Medicine

JF - Cell Reports Medicine

SN - 2666-3791

IS - 8

M1 - 100373

ER -

ID: 279634752